Vaccine Info

VLA1601 Zika Vaccine

Authored by
Staff
Last reviewed
January 13, 2024
Share

VLA1601 Zika Vaccine

Valneva SE's VLA1601 is a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide. VLA1601 was developed on the original manufacturing platform of Valneva's licensed Japanese Encephalitis vaccine, IXIARO®, which was further optimized. Valneva plans to re-initiate clinical development in the first quarter of 2024.

France-based Valneva is a specialty vaccine company focused on preventing diseases with significant unmet needs. Valneva's vaccine portfolio includes two commercial vaccines for travelers.

VLA1601 Zika Vaccine Indication

VLA1601 is a vaccine candidate indicated to prevent Zika infection. First identified in Uganda in 1947 in monkeys, Zika was later identified in humans in 1952. Since 2015, Zika outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and the Americas. Led by Brazil, 10 countries account for about 89% of Zika cases recorded between 2014 and 2023. As of early 2024, Zika outbreaks have been reported by the Pan American Health Organization (PAHO) throughout South and Central America.

According to the World Health Organization, there is scientific consensus that ZIKV is a cause of microcephaly and Guillain-Barré syndrome.

VLA1601 Zika Vaccine Dosage

In a phase 1 clinical trial, VLA1601 was administered intramuscularly in the deltoid muscle. Each dose is administered intramuscularly in the deltoid muscle on Days 0 and 28. Also, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses.

VLA1601 Zika Vaccine News

November 9, 2023 - The Company announced ZIKA VACCINE CANDIDATE – VLA1601 re-initiation of clinical development with further program evaluation planned.

March 30, 20Valneva'seva's Chief Medical Officer, Juan Carlos Jaramillo, MD, will host a discussion on the opportunities and challenges for developing Zika vaccines on April 4, 2023.

VLA1601 Clinical Trial

Valneva has concluded the Phase 1 trial. First Posted: February 7, 2018; Last Update Posted: July 5, 2019.

Clinical Trials

No clinical trials found